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Inflammation is typically induced in response to a microbial infection. The release of 
proinflammatory cytokines enhances the stimulatory capacity of antigen-presenting 
cells, as well as recruits adaptive and innate immune effectors to the site of infection. 
Once the microbe is cleared, inflammation is resolved by various mechanisms to avoid 
unnecessary tissue damage. Autoimmunity arises when aberrant immune responses 
target self-tissues causing inflammation. In type 1 diabetes (T1D), T cells attack the insu-
lin producing β cells in the pancreatic islets. Genetic and environmental factors increase 
T1D risk by in part altering central and peripheral tolerance inducing events. This results 
in the development and expansion of β cell-specific effector T cells (Teff) which mediate 
islet inflammation. Unlike protective immunity where inflammation is terminated, auto-
immunity is sustained by chronic inflammation. In this review, we will highlight the key 
events which initiate and sustain T cell-driven pancreatic islet inflammation in nonobese 
diabetic mice and in human T1D. Specifically, we will discuss: (i) dysregulation of thymic 
selection events, (ii) the role of intrinsic and extrinsic factors that enhance the expansion 
and pathogenicity of Teff, (iii) defects which impair homeostasis and suppressor activity 
of FoxP3-expressing regulatory T cells, and (iv) properties of β cells which contribute to 
islet inflammation.
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iNTRODUCTiON
Type 1 diabetes (T1D) is an autoimmune disease characterized by the chronic inflammation of 
the pancreatic islets of Langerhans (1–4). Islet inflammation is typically marked by infiltrating 
adaptive and innate immune effectors. Insulitis progresses over time and when a sufficient amount 
of β cell mass has been rendered nonfunctional and/or destroyed, hyperglycemic blood levels are 
achieved, and clinical diabetes established. The immune mechanisms mediating β cell autoim-
munity are heterogeneous, as reflected by the nature of the islet infiltrate and the age of clinical 
onset. Nevertheless, T1D is generally viewed as a T cell-driven autoimmune disease, particularly 
for the more prevalent and aggressive type of T1D that develops in children and adolescents versus 
adults (5–17). A T cell-independent subtype of T1D, however, may also exist that is thought to 
be largely mediated by innate immune effectors (18, 19). The events leading to the loss of β cell-
specific tolerance and chronic islet inflammation are complex, and influenced by both genetic and 
environmental factors (20–22).
Type 1 diabetes is polygenic with more than 20 insulin-dependent diabetes mellitus (IDDM) 
genetic loci identified that are associated with increased or decreased risk for T1D (23–28). The 
strongest genetic association is with the human leukocyte antigen locus (IDDM1), and particular 
FigURe 1 | Dysregulated thymic and peripheral events culminate in chronic islet inflammation. In general, overt diabetes results from the gradual loss of functional 
insulin producing β cells due to the inflammatory environment driven by infiltrating self-reactive T cells and antigen-presenting cell (APC). Although β cell-specific 
T cell clones are detected in both healthy and type 1 diabetes (T1D) susceptible individuals, a number of factors promote T1D development in the latter population. 
Decreased efficiency of negative selection in the thymus, either due to altered tissue-specific antigen expression or due to T cell receptor (TCR) signaling, allows  
for the increased escape of β cell-specific T cell clones into the periphery. In addition, β cell-specific Foxp3+Treg development may also be suboptimal due to 
dysregulation of TCR signaling. In the periphery, β cell-specific T cells are stimulated in the pancreatic lymph nodes (pLN) by APC derived from the islets, leading to 
effector T cell (Teff) differentiation. These pathogenic Teff then infiltrate the islets and drive inflammation leading to reduced β cell function and/or survival. Not all islets 
are infiltrated potentially due to an immature phenotype and reduced autoantigen expression by β cells. Ongoing islet inflammation also leads to the generation of 
neoautoantigens either directly in β cells or during antigen processing by APC. The presentation of neoautoantigens within the pLN promotes the activation and 
expansion of additional Teff pools. These events amplify and drive a chronic state of islet inflammation leading to impaired functional β cell mass and clinical onset  
of T1D.
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class I and II haplotypes, consistent with a key role for T  cells 
in T1D (29, 30). A number of genes regulating T, B, and innate 
cell immunobiology are also linked with T1D, as are genetic vari-
ants intrinsic to β cells, which deleteriously affect β cell function 
and/or responses to inflammation (31–37).
The identity and role of environmental factors in T1D are 
poorly understood. The most common hypothesis is that micro-
bial infections initiate and/or exacerbate islet inflammation in 
genetically susceptible individuals (38, 39). For instance, T1D is 
associated with enteroviruses such as coxsackievirus B1 (40–44). 
Viral infection of β cells may result in direct cytolysis and/or 
elicit local inflammation that initiates and/or drives autoimmun-
ity (45–47). The gut microbiota also has a profound regulatory 
effect on β cell autoimmunity (48, 49). In the nonobese diabetic 
(NOD) mouse, a spontaneous model of T1D, β cell destruction 
can be either promoted or prevented by changes in the composi-
tion of the gut microbiota (50, 51). Here bacterial components 
and metabolites are thought to impact the activation and/or 
differentiation status of innate and adaptive immune effectors. 
Longitudinal studies of at risk subjects also indicate a role for gut 
microbiota in human T1D (52–54).
The T  cell-related events that drive chronic islet inflamma-
tion in T1D stem from dysregulation of central and peripheral 
tolerance, alterations in self-antigen processing, and modified β 
cell responses (Figure  1). Here, we discuss how events critical 
for initiating and amplifying the development of T cell-mediated 
islet inflammation are regulated in NOD mice and human T1D.
THYMiC ORigiNS OF DiABeTOgeNiC  
T CeLLS: SeTTiNg THe STAge FOR  
iSLeT iNFLAMMATiON
The generation of an autoreactive T  cell receptor (TCR) 
reper toire in the periphery is established in part by inefficient 
negative selection of anti-self-single positive thymocytes (SP) 
in the thymus (55, 56). Early in ontogeny negative selection is 
lax, resulting in increased escape of anti-self-SP (57–59). This 
temporal decrease in negative selection and elevated survival of 
β cell-specific clonotypes may help explain the predominance of 
T1D onset in childhood. With time, changes in thymic structural 
organization and maturation of thymic antigen-presenting cells 
(APC) leads to more efficient negative selection and increased 
death of autoreactive SP (57).
Key mediators of negative selection are medullary thymic 
epithelial cells (mTEC) and dendritic cells (DC). Notably, mTEC 
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express and present several tissue-specific antigens (TSA) 
(60–63). Recognition of MHC-self-peptide complexes with 
increasing avidity/affinity results in elevated TCR signaling and 
SP apoptosis. Dysregulation of negative selection generates a 
peripheral pool of anti-self-T cells displaying increased avidity/
affinity, and likely an enhanced “pathogenic potential.”
Parameters influencing the efficiency of negative selection 
both intrinsic and extrinsic to thymocytes have been linked to 
the development of β cell-specific T cells and T1D. Thymocyte 
intrinsic properties reported in NOD mice have included 
reduced SP sensitivity to apoptosis and altered double positive 
thymocyte differentiation to SP (64–67). In humans, TCR signal-
ing needed to drive apoptosis of β cell-specific SP may be limited 
by a T1D-associated variant of the protein tyrosine phosphatase 
non-receptor 22 (PTPN22) gene (31, 32). PTPN22 is a negative 
regulator of TCR signaling, and elevated phosphatase activity 
by PTPN22 is predicted to reduce TCR signaling strength and 
diminish apoptosis induction in SP (68). An increase in PTPN22 
activity may also limit thymic development of β cell-specific 
FoxP3-expressing regulatory CD4+ T  cells (FOXP3+Treg), 
which is dependent on high(er) avidity/affinity recognition of 
self-peptide.
Thymocyte extrinsic factors that impact negative selec-
tion include aberrant expression of TSA in the medulla. The 
importance of thymic expression and presentation of TSA 
is readily evident in mice and humans deficient of the tran-
scription factor autoimmune regulator (AIRE) (60, 69). Lack 
of AIRE, which drives expression of select TSA by mTEC, 
results in inefficient thymic negative selection and reduced 
development of tissue-specific Foxp3+Treg, leading to multio-
rgan autoimmunity in mice (70–74). Similarly, aberrant AIRE 
expression and function in humans results in the development 
of autoimmune polyendorinology candidiasis and ectodermal 
dysplasia (APECD) in which a variety of organs are targeted 
by T  cells; notably a subset of APCED patients develop T1D 
(75, 76). Reduced AIRE expression has been reported in NOD 
mice, which reflects not only T1D development but also T cell-
mediated inflammation of other tissues such as the thyroid, 
salivary, and lacrimal glands (77).
In human T1D, a strong genetic association is linked to the 
insulin encoding gene INS2 found in IDDM2 (78). Insulin is 
believed to be a key autoantigen driving human T1D, which is 
supported by studies in NOD mice (79–81). INS2 is preceded 
by a variable number of tandem repeats (VNTRs). Individuals 
that have 26–63 VNTRs, associated with decreased thymic INS2 
expression, have an increased risk of developing T1D. In contrast, 
INS2 expression is increased with VNTRs ranging between 140 
and 210, which in turn is associated with a protective phenotype 
(82, 83). Reduced thymic insulin expression is expected to both 
limit negative selection and development of insulin-specific 
SP and FOXP3+Treg, respectively. Future studies are needed 
to directly demonstrate that thymic selection is dysregulated, 
and contributes to an expanded β cell-specific peripheral T cell 
pool in human T1D. Whether defects in thymic selection and 
development of β cell-specific T cells are necessary only early on 
or required throughout the disease process is another issue that 
needs to be tackled.
It is noteworthy that β cell-specific T  cells are detected in 
the blood of healthy individuals, likely reflecting in part the 
reduced efficiency of thymic negative selection early in ontog-
eny. However, the phenotype of circulating β cell-specific T cells 
is distinct in T1D patients versus healthy subjects (84–89). 
The former exhibit mostly an effector/memory phenotype 
and expression of proinflammatory cytokines consistent with 
ongoing β cell autoimmunity (84–88). These findings indicate 
that in addition to the TCR repertoire, other factors contribute 
to the differentiation and expansion of diabetogenic effector 
T cells (Teff). For instance, the extent of tissue destruction and 
lethality of AIRE deficiency in mice is influenced by genotype 
with AIRE-deficient NOD versus C57BL/6 mice exhibiting more 
severe systemic autoimmunity (90, 91). Additionally, distinct 
TCR repertoires have been found in NOD mice in contrast to 
MHC matched C57BL/6 mice (92). Overall, dysregulation of 
thymic selection events in NOD mice acts as a precursor for islet 
inflammation.
eXTRiNSiC AND iNTRiNSiC FACTORS 
PROMOTe PATHOgeNiC eFFeCTOR  
T CeLLS iN T1D
The initiation of islet inflammation in NOD mice and humans 
is ill-defined. In NOD mice pancreatic remodeling shortly after 
birth is thought to play a key role starting the diabetogenic 
response (93, 94). Remodeling of the pancreas results in a wave 
of β cell apoptosis and release of antigens which are endocytosed 
by resident macrophages and DC (95). These APC then traffick 
to the draining pancreatic lymph nodes (pLN) to prime β cell-
specific T cells and promote Teff differentiation (96, 97). Once 
established Teff migrate into the islets and mediate inflammation 
(97–99).
As alluded to above, shifts in the composition of the gut 
microbiota early in ontogeny are also believed to play a key role in 
regulating Teff differentiation in both mice and humans. Systemic 
release of microbiota-derived products can activate APC that in 
turn prime β cell-specific T  cells providing an “environmental 
trigger” to incite T1D development (48). NOD mice in which 
the response to the microbiome is limited due to a deficiency in 
the Toll-like receptor adaptor protein MyD88, exhibit reduced 
β cell-specific Teff reactivity and diabetes incidence (50, 100). 
Strikingly, diabetes is prevented in NOD mice housed under 
germ-free conditions and inoculated with microbiota derived 
from MyD88-deficient animals (50), demonstrating that the 
microbiota also has a protective role in T1D. A less diverse gut 
microbiota in young individuals at risk for T1D is associated with 
progression to clinical diabetes (54). Changes in the gut micro-
biome have also been linked to the female bias of T1D in NOD 
mice (100). Interestingly, studies show that the lymphopenic 
environment in neonatal mice induces naïve T  cells to rapidly 
expand and transition into a memory-like phenotype, that in 
turn is influenced by gut microbiota (101–104). Expansion of 
memory-like T cells, also seen in newborn humans, may enhance 
the pathogenic potential of the peripheral T cell pool and favor 
the development of autoimmunity in susceptible individuals.
4Clark et al. The Pathogenesis of Autoimmune Diabetes
Frontiers in Immunology | www.frontiersin.org December 2017 | Volume 8 | Article 1898
Both CD4+ and CD8+ T cells are required for efficient β cell 
destruction in NOD mice (105). Islet CD8+ T  cells primarily 
mediate β cell destruction by a cognate interaction involving 
perforin and granzyme B-, and Fas-Fas ligand-mediated killing 
(106, 107). On the other hand, islet CD4+ T  cells drive β cell 
destruction in a bystander manner via secretion of proinflamma-
tory cytokines. CD4+ and CD8+ T cells are also detected in the 
islets of diabetic subjects, with CD8+ T cells often predominating 
(6, 106). Several β cell autoantigens are recognized by the islet 
infiltrating T cells, and a number of these are similarly targeted 
in both the NOD and human diabetogenic responses including 
glutamic acid decarboxylase 65, proinsulin, insulin B chain, islet 
antigen-2, and islet-specific glucose-6-phosphatase catalytic 
subunit-related protein (108).
The majority of CD4+ and CD8+ T cells infiltrating the islets 
of NOD mice and T1D subjects exhibit a T helper 1 (Th1) 
effector phenotype, marked by IFNγ secretion (109). Increased 
Th17 cells are seen in the islets of NOD mice and the pLN of 
T1D subjects (109–111). The role of Th17  cells in mediating 
islet inflammation, however, is ill-defined. Elevated local levels 
of IFNγ are believed to establish a feed-forward loop that drives 
islet pathology. Based on NOD mouse studies, IFNγ secreted 
by islet CD4+ (and CD8+) Teff results in local upregulation of 
chemotactic cues that induce additional T, B, and innate cells 
to migrate into the islets, as well as promote islet retention of 
these effectors (109, 112). IFNγ also activates islet resident 
APC and stromal cells to elevate production of additional 
inflammatory mediators, such reactive oxygen species, which 
impair function and mediate β cell necrosis (107, 113, 114). 
Furthermore, IFNγ in the context of IL-1β and TNFα induces 
β cell apoptosis (113, 114).
Another proinflammatory cytokine thought to contribute 
to islet inflammation is IL-21 which is elevated in T1D patient 
serum (115). Notably, the murine IL-21 gene is located in the 
Idd3 locus and IL-21 receptor (R) deficiency prevents T1D 
in NOD mice (116). CD4+ T follicular helper cells, which are 
increased in the pLN of NOD mice, are the primary source of 
IL-21 (112, 117–119). IL-21 has a critical role in supporting B cell 
development and antibody production. B cells, serving as APC, 
are required for efficient β cell destruction in NOD mice and 
likely in human T1D (117, 118, 120, 121). IL-21 also enhances 
maintenance of CD8+ Teff by preventing exhaustion during 
chronic inflammation (122, 123). Interestingly, the pathogenicity 
of β cell-specific CD8+ T cells is dependent on IL-21R expression 
(124, 125).
Defects intrinsic to Teff are also thought to facilitate chronic 
islet inflammation. Variants of the CTLA4 gene are linked to 
T1D susceptibility in both NOD mice (Idd5.1) and human T1D 
(IDDM12) (33, 126). CTLA-4 which binds to the costimulatory 
molecules CD80 and CD86 expressed on APC, is a negative regu-
lator of T cell activation and proliferation (34). Polymorphisms 
in the human CTLA4 gene region are associated with reduced 
mRNA levels and a decrease in expression of the soluble (s) 
CTLA-4 isoform (33, 34, 126). sCTLA-4 also negatively regulates 
TCR signaling (33, 34, 126). Reduced expression of CTLA-4 and 
sCTLA-4 is expected to facilitate expansion of β cell-specific 
T  cells. This scenario is consistent with the exacerbated β cell 
autoimmunity seen in NOD mice expressing a diabetogenic TCR 
transgene and lacking CTLA-4 expression (127). Noteworthy is 
that both NOD-derived and human T1D Teff also exhibit reduced 
sensitivity to Foxp3+Treg-mediated suppression (128, 129). 
In sum, the culmination of a variety of extrinsic and intrinsic 
factors enables Teff to expand, persist, and in turn amplify islet 
inflammation.
DeFeCTS iN THe Foxp3+Treg POOL 
CONTRiBUTe TO T1D
In addition to Teff that are resistant to regulatory mechanisms 
that limit expansion and function, evidence indicates that the 
Foxp3+Treg pool is compromised in T1D (130, 131). Here, 
dysregulation of Foxp3+Treg homeostasis is thought to permit 
preferential differentiation and expansion of pathogenic β cell-
specific Teff. Foxp3+Treg have an essential role in regulating 
immune homeostasis and reactivity to self (132–135). The lack of 
thymic development of Foxp3+Treg due to deficient expression 
or function of the FoxP3 transcription factor, results in systemic 
autoimmunity in both mice and humans. Foxp3+Treg mediate 
suppression of T cells and other immune effectors via multiple 
mechanisms including cell-contact dependent suppression, and 
secretion of anti-inflammatory cytokines and mediators such 
as IL-10, TGFβ1, and IL-35, and adenosine, respectively (136). 
Foxp3+Treg also function as an “IL-2 depot” to deprive Teff of 
IL-2 needed for expansion (136). The latter is mediated by con-
stitutive expression of CD25, the α subunit of the IL-2R (136). 
Therefore, Foxp3+Treg, expressing the high affinity IL-2R, are 
able to out compete Teff for IL-2, which transiently express high 
affinity IL-2R.
IL-2 is essential for Foxp3+Treg homeostasis, expansion, and 
function (136). Unlike conventional T cells, Foxp3+Treg do not 
produce IL-2 due to FoxP3-mediated negative regulation of Il2 
transcription. Therefore, Foxp3+Treg are dependent on T  cells 
and DC as IL-2 sources (136). This dependency is thought to 
enable Foxp3+Treg to more readily sense and respond to ongoing 
inflammation. Accordingly, defects in the IL-2/IL-2R axis have 
been described in the NOD model and human T1D (137–142). 
In NOD mice, an Il2 variant located in Idd3 results in reduced 
levels of IL-2 expression by Teff, and impaired survival and func-
tion of islet resident Foxp3+Treg (130, 143). Increased levels of 
proinflammatory cytokines, such as IFNγ and IL-6 that down-
regulate FoxP3 expression may also promote dedifferentiation of 
islet Foxp3+Treg into a Teff-like subsets (144, 145). These events 
lead to a progressive loss of islet Foxp3+Treg suppression, thereby 
“releasing the brakes” and favoring pathogenic Teff expansion.
The frequency of FOXP3+Treg found in blood is largely 
unaffected in T1D subjects (140, 141, 146–148). However, 
FOXP3+Treg from T1D subjects exhibit reduced suppressor 
function measured in vitro (128, 129). This aberrant activity is 
linked to T1D risk variants of IL2RA (CD25) and PTPN2, a phos-
phatase involved in IL-2R signaling (149). Notably, FOXP3+Treg 
expressing these variants display reduced IL-2R signaling that 
in turn correlates with limited suppressor activity (149, 150). 
Defects in IL-2R signaling have led to clinical studies testing 
whether low-dose IL-2 therapy enhances the FOXP3+Treg pool 
5Clark et al. The Pathogenesis of Autoimmune Diabetes
Frontiers in Immunology | www.frontiersin.org December 2017 | Volume 8 | Article 1898
in T1D subjects (149, 151). This approach has been effective in 
preventing and/or reversing diabetes in NOD mice by increasing 
the number and function of islet Foxp3+Treg (149, 152). One 
key question not addressed is the specificity of FOXP3+Treg in 
T1D subjects. Reduced thymic development of β cell-specific 
FOXP3+Treg, as discussed above, would be expected to limit the 
“anti-diabetogenic” effects of the peripheral FOXP3+Treg pool.
AMPLiFYiNg THe PATHOgeNiC 
eFFeCTOR T CeLL ReSPONSe VIA 
NeOAUTOANTigeNS
Recent findings have demonstrated that the proinflammatory 
milieu of the islets promotes processing of “neoautoantigens” 
(153). Importantly, these neoautoantigens are only found in the 
periphery so that corresponding T  cell clonotypes, not deleted 
in the thymus and possibly expressing high affinity TCR, can 
be recruited into the inflammatory response. Neoautoantigens 
are generated via posttranslational modifications (PTM), such 
as deamidation by tissue transglutaminase (tTG) (153). PTM 
can occur during APC antigen processing or directly in β cells 
(154). tTG-dependent deamidation of a proinsulin C-peptide 
for instance is detected in both human DC and islets under 
inflammatory conditions (154). Notably the resulting modified 
peptide is recognized by CD4+ T cells derived from T1D subjects. 
The MHC binding and in turn T cell stimulatory properties of 
peptides can also be enhanced by deamidation (155).
Neoautoantigens consisting of hybrid peptides have recently 
been identified. In NOD mice hybrid insulin peptides are gener-
ated via covalent crosslinking of a proinsulin C peptide with 
peptides derived from naturally occurring cleavage products 
produced in the β cell secretory granules (156). In addition to 
ongoing inflammation, PTM occurs via endoplasmic reticulum 
stress, which can be induced in β cells by the normal physi-
ological demands associated with high levels of insulin secretion 
(157). Therefore, it is possible that β cell neoautoantigens in 
addition to amplifying inflammation, play a role in initiating the 
diabetogenic response. Neoautoantigens are also generated at a 
transcriptional level. A mutation in the open reading frame of 
insulin mRNA generates a neoautoantigen that stimulates CD8+ 
T  cells from T1D subjects causing β cells lysis in  vitro (158). 
Alternative RNA splicing may be another mechanism leading 
to neoautoantigen expression, particularly since ~30% of genes 
in inflamed β cells undergo aberrant alternative splicing (159). 
In sum, β cell neoautoantigens serve as bona fide targets of patho-
genic CD4+ and CD8+ T cells. The breadth of the peptidome of 
neoautoantigens produced and presented, and the properties of 
neoautoantigen-specific T cells, in terms of frequency, avidity/
affinity, subset phenotype (e.g., pathogenic versus regulatory), 
and overall contribution to islet inflammation require further 
investigation.
β CeLL-iNTRiNSiC PROPeRTieS THAT 
RegULATe iSLeT iNFLAMMATiON
Studies have demonstrated that intrinsic properties of β cells also 
influence islet inflammation. For instance, CXCL10 is produced by 
β cells although the role of this chemokine in disease is controversial 
(160). CXCL10 regulates migration of CXCR3 expressing Teff 
and Foxp3+Treg into the islets (97–99, 161). Overexpression of 
CXCL10 in β cells accelerates T1D progression, and antibody 
blockade of CXCL10 prevents Teff migration into the islets of 
NOD mice (97–99, 161). On the other hand, Cxcr3 deficiency 
accelerates T1D by reducing islet resident Foxp3+Treg (162, 163). 
Therefore, depending on the context, β cells may affect inflamma-
tory and immunoregulatory events via CXCL10 production. The 
chemokine CCL2 is also secreted by β cells, and over-expression 
of ectopic CCL2 recruits tolerogenic CCR2-expressing DC and 
blocks T1D progression in NOD mice (164). Interestingly, NOD 
APC shows defective migration in response to CCL2, and human 
T1D patients have reduced serum levels of CCL2 (164–166). 
Additionally, β cells produce CXCL1 and CXCL2 that recruit 
CXCR2-expressing neutrophils to the islets, which contribute to 
stimulating β cell-specific T cell reactivity (167, 168). Overall, β 
cell produced chemotactic cues regulate the progression of the 
diabetogenic response.
Along with chemokines, β cells secrete the cytokine IL-1β, 
which at low levels promotes β cell proliferation, and enhances 
production of CCL2, CXCL1, CXCL2, and insulin (169, 170). 
However, IL-1β also primes leukocyte effector-mediated 
inflammation, and as noted above, IL-1β in the context of TNFα, 
and/or IFN-γ induces β cell apoptosis in  vitro (113, 114). 
Notably, glucagon-secreting α cells also produce IL-1β, indicat-
ing that other islet resident endocrine cells may also contribute 
to local inflammation (171, 172). Islet inflammation also 
induces upregulation of MHC class I and II on β cells to further 
increase β cell immunogenicity (173). Interestingly, a subpopu-
lation of β cells have been identified which under inflammatory 
conditions acquires resistance to immune-mediated destruc-
tion in NOD mice (174). The latter is associated with a more 
immature β cell phenotype coupled with reduced expression 
of autoantigens and upregulation of immunomodulatory 
molecules such as PD-L1, an inducer of T  cell exhaustion. 
A similar phenotype is seen for human β cells (174). Therefore, 
β cells not only contribute to islet inflammation but also adapt 
under the inflammatory conditions in order to persist. A bet-
ter understanding of the events regulating this dichotomy has 
important implications for the treatment of T1D patients via β 
cell replacement strategies for instance.
SUMMARY
Type 1 diabetes is complex involving genetic, epigenetic and 
environmental factors that influence adaptive and innate effector 
cell populations, which ultimately culminate in pathological, 
chronic islet inflammation (Figure 1). The heterogeneity associ-
ated with human T1D and in turn the nature of islet inflamma-
tion is expected to reflect the genotype of the individual, and type 
of environmental insult(s) encountered (20–22). These factors 
dictate which immune effectors are the key drivers of pathology, 
the pace of disease progression, and the degree of β cell dysregu-
lation and/or death. We propose that the rapid and aggressive 
T1D seen early in life is marked by a broad β cell-specific TCR 
repertoire with increased avidity/affinity due to insufficient 
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negative selection (57–59). This is coupled with β cell-specific 
Teff that are insensitive to peripheral tolerance inducing events, 
β cell-specific FOXP3+Treg with impaired suppressor activity, 
and β cells which readily promote islet inflammation (128, 129, 
147, 169, 170). Robust inflammation leads to increased β cell 
neoautoantigen production further amplifying the kinetics 
and overall inflammatory response (153, 154, 156, 158). Under 
these “ideal” conditions, early onset T1D develops. On the other 
hand, in individuals with only a partial complement of these 
key “disease components,” islet inflammation is less robust and 
the kinetics of T1D onset proportionately delayed. Defining 
the events driving early versus late(r) T1D onset is critical for a 
better understanding of how islet inflammation is regulated in 
humans. The latter is also important for developing rational and 
effective immunotherapies to prevent and/or treat T1D. Devising 
strategies to enhance thymic negative selection early in ontogeny 
for instance, would be expected to purge the diabetogenic TCR 
repertoire to prevent T1D. Indeed, approaches are currently 
being studied to manipulate thymic negative selection in the 
context of cancer treatment by expanding the T cell repertoire 
specific for self-tumor antigens (175–177). Altering the gut 
microbiome early in life may also prove to be an effective strategy 
to limit expansion of the anti-self-T cell repertoire and establish 
robust immunoregulation in the periphery. Administration of β 
cell neoautoantigens may augment the efficacy of antigen-based 
immunotherapies to block disease progression at later stages of 
T1D (157). Depending on the mode of administration, β cell 
neoautoantigens can be used to target the corresponding clono-
types by tolerizing pathogenic Teff and/or inducing/expanding 
FOXP3+Treg. In view of the heterogeneity in the immunopathol-
ogy of T1D, it is very likely these approaches and others currently 
being studied will need to be combined to effectively suppress the 
chronic islet inflammation and β cell autoimmunity long term.
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